Trial Comparing Three Single Dose Injections for Knee Osteoarthritis

NCT ID: NCT05492851

Last Updated: 2023-04-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-02
• Study Completion Date: 2023-01-11

Brief Summary

This study is a 3-arm, double-blind, randomized trial comparing the clinical outcomes of Zilretta, Synvisc One, and Monovisc for knee OA.

Detailed Description

Knee osteoarthritis (OA) is a leading cause of disability worldwide.1,2 Standard of care treatments for knee OA include activity modification, weight loss, therapeutic exercise and medications like non-steroidal anti-inflammatory drugs (NSAIDs). If these measures fail, injections like corticosteroids and hyaluronate (HA) can be helpful for pain control.3

The aforementioned injections have unique mechanisms of action. Steroid injections work through reducing joint inflammation, while HA works by lubricating and cushioning the joint. There are several varieties of steroids and HA injections that have been approved by the Food and Drug Administration for use in knee OA.

Among these variations are extended-release triamcinolone (Zilretta), hylan GF-20 (synvisc one), and hyaluronan (monovisc). While each are FDA approved and commonly used in orthopedic and sports medicine clinics, they have never been directly compared in any study. Therefore, when selecting a treatment for a patient, it is largely based on provider preference, not clinical data.

This study is a 3-arm, double-blind, randomized trial comparing the clinical outcomes of Zilretta, Synvisc One, and Monovisc for knee OA.

Conditions

Osteoarthritis, Knee

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Zilretta

Generic Name: Triamcinolone acetonide Zilretta is an extended-release synthetic corticosteroid indicated as an intra-articular injection for the management ofosteoarthritis pain of the knee.

5mL suspension of 32 mg of triamsinolone administered as a 1 dose parapatellar intra-articular injection.

Group Type: ACTIVE_COMPARATOR

Zilretta

Intervention Type: DRUG

Intra-articular injection to treat knee osteoarthritis

Synvisc One

Generic Name: Hylan G-F 20 Synvisc-One combines the three doses of SYNVISC (hylan G-F 20) which consists of hylan A (average molecular weight6,000,000 daltons) and hylan B hydrated gel in a buffered physiological sodium chloride solution, pH 7.2.

Each 10 mL syringe of Synvisc-One combines the three 2-mL doses (16 mg each) of a complete SYNVISC treatment regimen (48 mg). Synvisc-One belongs to a class of drugs called Intra-Articular Agents; Rheumatologics, Other.

10mL of Hylan G-F 20 administered as a 1 dose parapatellar intra-articular injection.

Group Type: ACTIVE_COMPARATOR

Synvisc-One 48 MG in 6 ML Prefilled Syringe

Intervention Type: DRUG

Intra-articular injection to treat knee osteoarthritis

Monovisc

Generic Name: Hyaluronan The Monovisc™ device is a proprietary high molecular weight hyaluronic acid (HA) viscosupplementation intended for the treatment of pain in patients with moderate osteoarthritis (OA) of the knee who have failed conservative non-pharmacological therapy and simple analgesics. The device is administered by a single injection via the para-patellar approach under sterile conditions.

4mL injection of Hyaluronan administered as a 1 dose parapatellar intra-articular injection.

Group Type: ACTIVE_COMPARATOR

Monovisc 88 MG Per 4 ML Prefilled Syringe

Intervention Type: DRUG

Intra-articular injection to treat knee osteoarthritis

Interventions

Zilretta

Intra-articular injection to treat knee osteoarthritis

Intervention Type: DRUG

Synvisc-One 48 MG in 6 ML Prefilled Syringe

Intra-articular injection to treat knee osteoarthritis

Intervention Type: DRUG

Monovisc 88 MG Per 4 ML Prefilled Syringe

Intra-articular injection to treat knee osteoarthritis

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age 25-85 years
• BMI < 40
• Diagnosis of unilateral knee OA
• Radiographic evidence of OA of the target knee (Kellgren-Lawrence grades 2-4)
• Continued OA pain in the target knee despite at least 6 weeks of: physical therapy and at least one of the following: activity modification (such as reducing impact on the knee), weight loss, and a 2 week trial of NSAID / acetaminophen.
• Knee Osteoarthritis Outcomes Score (KOOS)-Pain subscale 20-65
• Working knowledge of English language (to be able to complete all outcome scores)
• Ability to attend all follow-up appointments

Exclusion Criteria

• 3+ effusion of the target knee (stroke test grading system)
• Prior injection therapy:

• Steroid injection in target knee in the last 3 months
• Viscosupplementation in target knee in the last 6 months
• PRP in the target knee in the last 6 months
• Cellular treatments in index knee (bone marrow, amniotic suspensions etc) 1 year
• Participation in any experimental device or drug study within 1 year before screening visit
• Oral or IM steroids in the last 3 months (Inhaled steroids used in the treatment of asthma/allergies are permitted)
• Medical condition that may impact outcomes of procedure including:

• Systemic inflammatory disorders that impact the joints like rheumatoid arthritis, lupus, etc
• Undergoing current cancer treatment (other than non-melanoma skin malignancies)
• Taking immunosuppressants
• Previous cartilage repair procedure on the injured cartilage surface (ie, OATS, ACI, MFX) in the last 5 years
• Previous surgery at the target knee within the past 1 year
• Any degree of cognitive impairment
• Symptomatic OA of any other joint in the lower limbs
• Pregnancy, lactating, or intent to become pregnant during treatment period (Female participants will be asked if they are pregnant, lactating, or intend to become pregnant during treatment)
• Gout, Pseudogout (including radiographic evidence of chondrocalcinosis)
• History of infection or current infection at the affected joint
• Smoking (Former smokers< 1 year from quit date)

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ohio State University

OTHER

Sponsor Role: lead

Responsible Party

Michael Baria

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Michael Baria

Role: PRINCIPAL_INVESTIGATOR

Ohio State University

Locations

Jameson Crane Sports Medicine Institute

Columbus, Ohio, United States

Ohio State Outpatient Lewis Center

Lewis Center, Ohio, United States

Countries

United States

Other Identifiers

2022H0168

Identifier Type: -

Identifier Source: org_study_id